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Adoptive immunotherapy with functional T cells is
potentially an effective therapeutic strategy for com-
bating many types of cancer and viral infection.
However, exhaustion of antigen-specific T cells rep-
resents a major challenge to this type of approach. In
an effort to overcome this problem, we reprog-
rammed clonally expanded antigen-specific CD8+
T cells from an HIV-1-infected patient to pluripo-
tency. The T cell-derived induced pluripotent stem
cells were then redifferentiated into CD8+ T cells
that had a high proliferative capacity and elongated
telomeres. These ‘‘rejuvenated’’ cells possessed
antigen-specific killing activity and exhibited T cell
receptor gene-rearrangement patterns identical to
those of the original T cell clone from the patient.
We also found that this method can be effective for
generating specific T cells for other pathology-asso-
ciated antigens. Thus, this type of approach may
have broad applications in the field of adoptive
immunotherapy.
INTRODUCTION
T cells play a central role in acquired immunity and the configu-
ration of systemic immunity against pathogens. In particular,
cytotoxic T lymphocytes (CTLs) are major components of this
systemic response to microorganisms, viral infections, and
neoplasms (Greenberg, 1991; Zhang and Bevan, 2011). T cells114 Cell Stem Cell 12, 114–126, January 3, 2013 ª2013 Elsevier Inc.initiate their proliferative and effector functions upon human
leukocyte antigen (HLA)-restricted recognition of specific
antigen peptides via T cell receptors (TCRs). This is greatly bene-
ficial in enabling the selective recognition and eradication of
target cells, and also in long-term immunological surveillance
by long-lived memory T cells (Butler et al., 2011; Jameson and
Masopust, 2009; MacLeod et al., 2010). However, viruses in
chronic infection or cancers often hamper or escape the T cell
immunity by decreasing the expression of molecules required
for T cell recognition or by inhibiting antigen presentation (Virgin
et al., 2009). In addition, continuous exposure to chronically ex-
pressed viral antigens or cancer/self-antigens can drive T cells
into an ‘‘exhausted’’ state. This is characterized by loss of
effector functions and the potential for long-term survival and
proliferation, ultimately leading to the depletion of antigen-re-
sponding T cell pools (Klebanoff et al., 2006; Wherry, 2011).
The infusion of ex vivo-expanded autologous antigen-specific
T cells is being developed clinically for T cell immunotherapy.
However, up to now, highly expanded T cells have not proven
to be particularly effective (June, 2007). This is in part explained
by losses of function that occur during the ex vivo manipulation
of patient autologous T cells. In another instance, genetic modi-
fication of antigen receptors is an ambitious but only partially
successful way to add desired antigen specificity to nonspecific
T cells (Morgan et al., 2006; Porter et al., 2011). The therapeutic
effect also strongly depends on the extent of functional loss that
occurs during the ex vivo manipulation of T cells and on the
stability of exogenous antigen receptor expression specific to
target molecules in the presence of the endogenous TCR genes
(Bendle et al., 2010; Brenner and Okur, 2009).
For the purpose of overcoming these obstacles, the thera-
peutic potential of induced pluripotent stem cells (iPSCs) is being
Cell Stem Cell
Rejuvenation of T Cells through Reprogrammingexplored. Embryonic stem cells (ESCs) or iPSCs have the
capacity for self-renewal while maintaining pluripotency (Taka-
hashi et al., 2007) and could potentially form the basis for the
unlimited induction of antigen-specific juvenile T cells. However,
there are challenges to this approach aswell, given that methods
for the differentiation and immunological education of ESCs and
iPSCs, or indeed that of intermediate hematopoietic stem and/or
progenitor cells, into fully matured functional human T cells are
not well established (Timmermans et al., 2009). Reprogramming
the nuclei of lymphocytes was historically performed for studying
whether terminally differentiated or fully matured somatic cells
could revert to a pluripotent state. The first demonstration of
lymphocyte reprogramming employed somatic cell nuclear
transfer in murine B and T cells, proving that terminally differen-
tiated somatic cells were reprogrammable (Hochedlinger and
Jaenisch, 2002). Reprogramming murine B cells into pluripotent
stem cells by iPSC technology also provided definite proof for
fate reversibility in fully matured somatic cells (Hanna et al.,
2008). From another point of view, nuclear reprogramming of
lymphocytes is seen as having applications for regenerative
medicine different than those for scientific research. The irre-
versible rearrangement of genes encoding immunoglobulins
and TCRs was recognized solely as a genetic marker in somatic
cell nuclear transfer and iPSC research. However, the preserved
rearrangements in genomic DNA can also provide a blueprint of
‘‘educated’’ weapons for attacking cancers and pathogens in
adoptive immunotherapy. Although several groups have re-
ported the generation of T cell-derived iPSCs (T-iPSCs), their
clinical applications have yet to be thoroughly explored (Brown
et al., 2010; Loh et al., 2010; Seki et al., 2010; Staerk et al., 2010).
In the present study, we chose a T cell clone specific to an HIV
type 1 (HIV-1) epitope of known structure to act as a generic rep-
resentation of iPSC-mediated T cell regeneration. We success-
fully induced iPSCs from antigen-specific T cells and redifferenti-
ated them into functional T cells. Thismay act as proof of concept
for the application of ‘‘rejuvenated’’ T cells in treating various
diseases. Crucial to this concept was that T-iPSCs retained the
assembled ‘‘endogenous’’ TCRgeneseven after being subjected
to nuclear reprogramming. Furthermore, redifferentiated T cells
showed the same pattern of TCR gene arrangement as that in
the original T cells. These features may therefore serve as the
foundation for the reproduction of unlimited numbers of T cells
that express desired TCRs conferring to antigen specificity.
RESULTS
Reprogramming an Antigen-Specific Cytotoxic T Cell
Clone into Pluripotency
To establish T cell-derived iPSCs, wemagnetically separated the
CD3+ T cell population from peripheral blood mononuclear cells
(PBMCs) of healthy volunteers. The isolated CD3+ T cells were
stimulated with human CD3 and CD28 antibody-coated mi-
crobeads (a-CD3/28 beads) in the presence of interleukin-2
(IL-2). We then transduced the activated CD3+ T cells with sepa-
rate retroviral vectors that individually code for OCT3/4, SOX2,
KLF4, and c-MYC. Human ESC-like colonies were obtained
within 25 days of culture (Figure S1A available online).
We also isolated PBMCs from an HLA-A24-positive patient
with a chronic HIV-1 infection. CD8+ CTL clones specific for anCeantigenic peptide (amino acids [aa] 138–145) from the HIV-1
Nef protein (Nef-138-8(WT); RYPLTFGW) (Altfeld et al., 2006)
were established. One of the clones, H25-#4, was stimulated
using a-CD3/28 beads in the presence of IL-2 and then trans-
duced simultaneously with six retroviral vectors encoding
OCT3/4, SOX2, KLF4, c-MYC, NANOG, and LIN28A. However,
we could not reprogram H25-#4 into pluripotency, possibly due
to the cells being in a low infectious and exhausted state, or
due to insufficient expression of the reprogramming factors. In
response, we attempted to increase transduction efficiency
and transgene expression by using two Sendai virus (SeV)
vectors. One of them encodes tetracistronic factors (OCT3/4,
SOX2, KLF4, and c-MYC) (Nishimura et al., 2011) with the miR-
302 target sequence (SeVp[KOSM302L]; K.N., M.O., and M.N.,
data not shown), and another encodes SV40 large T antigen
(SeV18[T]) (Fusaki et al., 2009). After transduction of phytohe-
magglutinin (PHA)-activated H25-#4 cells with the SeV vectors
in the presence of IL-7 and IL-15, sufficient numbers of human
ESC-like colonies appeared within 40 days of culture (Figure 1A).
Use of this SeV system and optimization of transduction condi-
tions greatly improved the reprogramming efficiency. It enabled
us to reprogram several CD8+ or CD4+ T cell clones specific to
pp65 antigen in cytomegalovirus (CMV), glutamic acid decarbox-
ylase (GAD) antigen in type 1 diabetes, and a-GalCer (Table 1).
The resultant CD3+ T cell- and H25-#4-derived ESC-like colo-
nies (TkT3V1-7 andH254SeVT-3, respectively) exhibited alkaline
phosphatase (AP) activity and expressed the pluripotent cell
markers SSEA-4, Tra-1-60, and Tra-1-81 (Figures S1B–S1E
and 1B–1E). H254SeVT-3 expressed HLA-A24 (Figure 1F).
Both TkT3V1-7 and H254SeVT-3 also expressed human ESC-
related genes (Figures S1F and 1G). The expression of exoge-
nous reprogramming factors from the integrated provirus
(TkT3V1-7) was halted (Figure S1F), and nonintegrated SeV
genomic RNA was successfully removed from the cytosol by
RNAi or by self-degradation caused by temperature-sensitive
mutations (H254SeVT-3) (Figure 1H). Comparison of gene-
expression profiles revealed that the gene-expression patterns
in the ESC-like cells were similar to those in human ESCs, but
differed significantly from those in peripheral blood (PB) T cells
(Figure S1G). Scant methylation of the OCT3/4 and NANOG
promoter regions was confirmed using bisulfite PCR, thus indi-
cating successful reprogramming (Freberg et al., 2007) (Figures
S1H and 1I). In addition, when injected into nonobese diabetic
severe combined immunodeficient (NOD-Scid) mice, those cells
formed teratomas containing characteristic tissues derived from
all three germ layers, which is indicative of pluripotency (Brivan-
lou et al., 2003) (Figures S3 and 2A). Therefore, those colonies
were confirmed as typical human iPSCs.
T-iPSCs Carry Preassembled TCR Genes from the
Original T Cell
Almost all TCRs are composed of heterodimerically associated
a and b chains. TCRA or TCRB gene (encoding a chain or b chain,
respectively) rearrangements are involved in normal ab T cell
development in the thymus. These rearrangements enabled us
to determine retrospectively whether the iPSCs were derived
from an ab T cell. The BIOMED-2 consortium designed multi-
plex-PCRprimers for analyzingTCRBgeneassemblies (vanDon-
genet al., 2003), andwedesigned theprimers for detectingTCRAll Stem Cell 12, 114–126, January 3, 2013 ª2013 Elsevier Inc. 115
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Figure 1. Generation of Human iPSCs from a CTL Clone
(A) Schematic illustration showing the generation of T-iPSCs from H25-#4 T cells using SeV vectors encoding polycistronicOCT3/4, SOX2, KLF4, and c-MYC, or
SV40 large T antigen. The ‘‘tapering’’ indicates the gradual replacement of culture medium with human iPSC medium.
(B–F) AP activity (B) and expression of pluripotency markers (SSEA-4, C; Tra-1-60, D; and Tra-1-81, E) and HLA-A24 (F) in H254SeVT-3 cells. Nuclei were
counterstained with DAPI. The scale bar represents 200 mm.
(G) Quantitative PCR for pluripotency genes in H25-#4, KhES3, TkT3V1-7, and H254SeVT-3 cells. Individual PCR reactions were normalized against 18S
ribosomal RNA (rRNA).
(legend continued on next page)
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Table 1. Generation of Human T-iPSCs from Various Patient-Derived T Cell Specimens
Antigen T Cell Source
Initial Cell
Number
No. of ESC-like
Colonies
No. of Colonies Picked up for
Establishing T-iPSC Clones Date (MM/YYYY)
HIV-1 Nef monoclonal T cell clone 4 3 105 7 7 05/2011
CMV pp65 polyclonal tetramer-sorted cells 5,000 15 15 07/2011
GAD monoclonal T cell clone 1 3 106 >100 not picked up 08/2012
5 3 105 >100 19 08/2012
a-GalCer FACS-sorted Va24+ cells 1 3 106 >100 not picked up 08/2012
5 3 105 >100 7 08/2012
Sample cells were transduced with OCT3/4, SOX2, KLF4, c-MYC, and SV40 large T-antigen by using two Sendai virus (SeV) vectors (SeVp
[KOSM302L] and SeV18[T]). After around 40 days, the number of embryonic stem cell (ESC)-like colonies were counted on the basis of morphology
and alkaline phosphatase (AP) activity. All established T cell-derived induced pluripotent stem cell (T-iPSC) lines were free from residual SeV vectors
(one example in the case of the HIV-1 Nef-specific T-iPSC clone is shown in Figure 1H). CMV, cytomegalovirus; GAD, glutamic acid decarboxylase;
FACS, fluorescence-activated cell sorting.
Cell Stem Cell
Rejuvenation of T Cells through Reprogramminggene assemblies (Figure S2). TCRB and TCRA gene assemblies
were identified as single bands representing each allele in
TkT3V1-7 and H254SeVT-3 (Figures S1H, S1I, 1J, and 1K).
We next confirmed the presence of an antigen-recognition site
on the TCR that consisted of three complementarity-determining
regions (CDR1, CDR2, and CDR3). CDR3 is the most diversifi-
able among the three because it spans the V(D)J-junction region,
where several random nucleotides (N or P nucleotides) are
inserted (Alt and Baltimore, 1982; Lafaille et al., 1989). We deter-
mined the CDR3 sequences of the assembled TCRA and TCRB
genes in TkT3V1-7 and H254SeVT-3 and identified a set of
productive TCRA and TCRB gene rearrangements (i.e., in-frame
junction with no stop codon) (Table S1 and Table 2). Further-
more, the sequences of CDR3 from H254SeVT-3 and H25-#4
were completely identical at both TCRA and TCRB gene loci.
These results indicated that the iPSCs established were
derived from a single T cell and that the antigen specificity en-
coded in the genomic DNA of the T cell was conserved during
reprogramming.
Redifferentiation of T-iPSCs into CD8 Single-Positive
T Cells Expressing the Desired TCR
Following the application of specific in vitro differentiation proto-
cols, iPSCs can give rise to mesoderm-derived cell types, espe-
cially hematopoietic stem and/or progenitor cells (Takayama
et al., 2008; Vodyanik et al., 2005) (Figure 2B). This was applied
to assess the capacity of T-iPSCs for hematopoietic differentia-
tion by coculturing on C3H10T1/2 feeder cells in the presence of
VEGF, SCF, and FLT-3L for the generation of CD34+ hematopoi-
etic stem and/or progenitor cells. On day 14 of culture, the cells
were transferred onto Delta-like 1-expressing OP9 (OP9-DL1)
feeder cells (Timmermans et al., 2009) and were cocultured in
the presence of FLT-3L and IL-7 (Ikawa et al., 2010) (Figure 2B).
After 21–28 days of culture, the hematopoietic cells differenti-(H) Detection of the remnants of SeV genomic RNAs by RT-PCR. Each colum
[KOSM302L] virus solution, and SeV18[T] virus solution. cDNAs from virus soluti
(I) Bisulfite sequencing analyses of the OCT3/4 and NANOG promoter regions in H
and methylated (Me) CpG dinucleotides, respectively.
(J) Multiplex PCR analysis to detect TCRB gene rearrangements in the H254SeVT
assemblies.
(K) Multiplex PCR analysis for detection of TCRA gene rearrangements (V-Ja ass
See Figures S1, S2, and S3 for additional data.
Ceated into CD45+, CD38+, CD7+, CD45RA+, CD3+, and TCRab+
T lineage cells (Figure S4). As was the case with TCRab trans-
genic mice (Borgulya et al., 1992) and chimeric mice derived
from ESCs produced through nuclear transplantation of T cells
(Serwold et al., 2007), aberrant expression of TCRab was
observed at the CD4/CD8 double-negative (DN) stage. Although
some of these T lineage cells differentiated into the CD4/CD8
double-positive (DP) stage and the more mature CD4 or CD8
single-positive (SP) stages (Figure 2C), we could not charac-
terize the small number of SP cells in more detail.
During thymocyte development, the CD4/CD8 DN and DP
stages correspond respectively to the TCRB-encoded b chain
and TCRA-encoded a chain assembly stages (von Boehmer,
2004). In the TCRB locus, the negative-feedback regulation of
gene assembly and the capacity to deter further rearrangement
are very strict (Khor and Sleckman, 2002). In the TCRA locus, by
contrast, negative-feedback regulation is relatively loose, and
further gene assembly of the preassembled gene, a phenomenon
known as ‘‘receptor revision,’’ tends to occur (Huang and Kana-
gawa, 2001; Krangel, 2009). In experiments using TCRa trans-
genic mice, the reactivation of Rag1 and Rag2, genes related
to recombination machinery, occurred in CD4/CD8 DP-stage
thymocytes, and gene assembly of endogenous Tcra was
observed (Padovan et al., 1993; Petrie et al., 1993). Such further
gene assembly would be exceedingly undesirable for our
purposes, because it would probably convert the tropism of
the TCR and render the redifferentiated T cells incapable of at-
tacking the previously targeted antigen. To determine whether
such receptor revision could occur in redifferentiating T lineage
cells, we collected CD1a DN- and CD1a+ DP-stage cells from
among the CD45+, CD3+, TCRab+, and CD5+ T lineage cells
and then analyzed the gene rearrangement of TCR messenger
RNAs (mRNAs) (Figures S5A–S5C). Nucleotide sequences of
TCRB mRNAs in the T lineage cells were identical to those inn represents the template cDNA synthesized from H254SeVT-3 cells, SeVp
on were the positive controls.
25-#4 and H254SeVT-3 cells. White and black circles represent unmethylated
-3 genome. Tubes A and B contain Vb-(D)Jb assemblies; Tube C contains D-Jb
emblies).
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Figure 2. Redifferentiation of T-iPSCs into T Cells
(A) Representative hematoxylin- and eosin-stained sections of a teratoma formed in a NOD/ShiJic-scidmouse testis. H254SeVT-3 differentiated into cell lineages
derived from endoderm (goblet cells in gut-like epithelial), mesoderm (smoothmyocytes in muscle tissue), and ectoderm (retina cells in pigmented epithelial). The
scale bar represents 100 mm.
(legend continued on next page)
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Rejuvenation of T Cells through Reprogrammingthe T-iPSCs at both the DN and DP stages. By contrast, some
TCRA mRNAs at the DN and DP stages were identical to those
in the T lineage cells, but others differed, and differing sequences
were observed more frequently at the DP stage than the DN
stage (Table S2). RAG1 and RAG2 expression were observed
at both the DN and the DP stages, though stronger expression
was observed at the DP stage (Figure S5D).
To create mature CD8 SP cells from T-iPSC-derived T lineage
cells without receptor revision, we focused on TCR signaling.
Turka et al. (1991) reported that TCR signaling via peptide-major
histocompatibility complex (MHC) complexes during positive
selection ends expression of RAG genes and prevents further
assembly of TCR genes. They also showed that mimicking
TCR signaling using CD3 antibodies had the same effect. There-
fore, we tried to stimulate the TCRs of redifferentiating T lineage
cells before the completion of the DN-to-DP transition (Fig-
ure 2B). For this experiment, we cultured T lineage-committed
cells on OP9-DL1, stimulated them with a-CD3/28 beads or
PHA (we defined this as the first stimulation) and then cocultured
them with irradiated HLA-A24 PMBCs in the presence of IL-7
and IL-15, which are required for the generation of memory
phenotype CD8+ T cells (Kaneko et al., 2009; Prlic et al., 2002;
Tan et al., 2002). After 14 days, CD8 SP cells appeared (Fig-
ure 2D). These were deemed to be derivatives of H254SeV-3
based on their expression of HLA-A24 (Figure 2E). These CD8
SP cells did not express the immature thymocyte marker
CD1a, but they were positive for CD56, which is expressed on
CD8+ T cells cultured in vitro (Lu and Negrin, 1994). In addition,
these cells expressed CD7 and some CD2, but not CD5. On
the one hand, they did not express PD-1, a marker of exhausted
T cells (Figure 2E). On the other hand, some of them expressed
the memory T cell markers CCR7, CD27, and CD28 simulta-
neously, thus representing a central memory T cell phenotype
(Figures 2F and 2G) (Romero et al., 2007).
To test whether the redifferentiated CD8 SP cells would recog-
nize the same epitope on the same HLA, the entire population of
redifferentiated T cells was mixed with the A24/Nef-138-8(WT)
tetramer and subjected to flow-cytometric analysis (Kawana-Ta-
chikawa et al., 2002). Most of the CD8 SP cells were stained
positively by the A24/Nef-138-8(WT) tetramer, but not by the
control tetramer, which represents HIV-1 envelope-derived
peptides (RYLRDQQLL; Figure 3A and data not shown). We
then collected the A24/Nef-138-8(WT) tetramer-reactive CD8+
cells and expanded them once again using a-CD3/28 beads or
PHA stimulation (defined as the second stimulation; Figure 3A).
Finally, after several independent redifferentiation experiments,
we obtained A24/Nef-138-8(WT) tetramer-reactive CD8 SP cells
(reT-1, reT-2.1, reT-2.2, and reT-3). As expected, sequence anal-
ysis of TCRA and TCRB mRNAs in the redifferentiated CD8 SP
cells revealed that the TCR gene rearrangement pattern was
identical to that in the H25-#4 original T cell clone (Figure 3B
and Table 1).(B) Schematic illustration of redifferentiation from T-iPSCs into T cells.
(C) Flow-cytometric analysis of the phenotypes of differentiating T lineage cells a
(D and E) Flow-cytometric analysis of the phenotypes of T cells at 60 days after
revealed CD8 single-positive maturation (D) and expression of several T cell mar
(F and G) Memory phenotypes of redifferentiated CD8+ T cells. There existed me
Data are representative of at least three independent experiments. See Figures S
CeTo determine whether the redifferentiated CD8 SP cells were
of the T cell lineage, we used quantitative PCR to compare
gene-expression profiles among redifferentiated CD8 SP cells,
PB CD4+ and CD8+ T cells, and the H25-#4 original T cell
clone. As shown in Figure 3C, the expression patterns of
CD3, CD4, and CD8 were similar among PB CD8+ T cells, re-
differentiated CD8 SP cells, and the H25-#4 original T cell
clone. However, the pattern differed from those in PB CD4+
T cells (Figure 3C). Cytotoxic ‘‘signature’’ genes such as gran-
zyme B (GZMB), perforin (PRF1), interferon-g (IFN-g; IFNG),
and FAS ligand (FASLG) were expressed in PB CD8+ T cells.
These genes were also expressed relatively strongly in redif-
ferentiated CD8 SP cells and in the H25-#4 original T cell clone;
that is, in already-primed T cells (Figure 3D). The expression
patterns of several factors involved in transcription or signal
transduction and of cell-surface molecules were similar among
PB CD8+ T cells, redifferentiated CD8 SP cells, and the H25-#4
original T cell clone (Figure 3E). To exclude the possibility that
the redifferentiated CD8 SP cells had acquired natural killer
(NK)-like properties during their coculture with OP9-DL1 or
PBMCs, we used a complementary DNA (cDNA) microarray
to analyze global gene-expression profiles in redifferentiated
CD8 cells, the H25-#4 original T cell clone, and PB NK
cells. Correlation and cluster analyses of the gene-expression
profile of the redifferentiated CD8 SP cells showed it to be
similar to that of the H25-#4 original T cell clone but different
from that of NK cells (Figures 3F and 3G). These data strongly
suggest that T-iPSCs are able to redifferentiate into CD8+
T cells that exhibit the same antigen specificity as that of the
original T cell.
Generation of Highly Proliferative T Cells through
T-iPSCs
Fewer than 105 T lineage cells were obtained from 3 3 105
T-iPSCs after coculture with C3H10T1/2 and OP9-DL1 cells.
However, they could be expanded to >108 cells with the first
stimulation (data not shown). After separating A24/Nef-138-
8(WT) tetramer-reactive CD8+ cells, we assessed the expansion
rate induced by the second stimulation and also assessed the
establishment of reT-1, reT-2.2, and reT-3. We found that these
cells expanded from 100-fold to 1,000-fold within 2 weeks in the
presence of IL-7 and IL-15, whereas the H25-#4 original T cell
clone expanded only about 20-fold (Figure 4A). Even after 100-
to-1,000-fold expansions, some cells still expressed central
memory T cell markers such as CCR7, CD27, and CD28 (Fig-
ure S6). Perhaps with passage through the iPSC state, wherein
telomerase activity is quite high (Marion et al., 2009; Takahashi
et al., 2007), re-elongation of shortened telomeres in the H25-
#4 original T cell clone gives the redifferentiated T cells high repli-
cative potential (Monteiro et al., 1996; Weng et al., 1998). In fact,
the redifferentiated T cells carried longer telomeres than the orig-
inal T cell clone (Figure 4B), an overall process that we callt 37 days after starting redifferentiation.
starting redifferentiation. Fluorescence-activated cell sorting (FACS) analyses
kers (E).
mory-phenotyped cells such as all positive for CCR7 (F), CD27, and CD28 (G).
3, S4, and S5 and Table S2 for additional data.
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Table 2. TCR Gene Rearrangements in H25-4, H254SeVT-3, or Redifferentiated CD8+ T Cells
Cell
Genome or
mRNA Productivity Rearrangement Sequence of Junctional Region
Va Ja 30Va P(N) 50Ja
TCRA
H25-4 genome productive TRAV8-3*01 TRAJ10*01 TGTGCTGTGGGT T TCACGGGAGGAGGAAACAAACTC
ACCTTTT
unproductivea TRAV13-1*01 TRAJ29*01 TGTGCAGCAA TCC TCAGGAAACACACCTCTTGTCTTT
H254SeVT-3 genome productive TRAV8-3*01 TRAJ10*01 TGTGCTGTGGGT T TCACGGGAGGAGGAAACAAACTC
ACCTTTT
unproductivea TRAV13-1*01 TRAJ29*01 TGTGCAGCAA TCC TCAGGAAACACACCTCTTGTCTTT
reT-1 mRNA productive TRAV8-3*01 TRAJ10*01 TGTGCTGTGGGT T TCACGGGAGGAGGAAACAAACTC
ACCTTTT
unproductivea TRAV13-1*01 TRAJ29*01 TGTGCAGCAA TCC TCAGGAAACACACCTCTTGTCTTT
reT-2.1 mRNA productive TRAV8-3*01 TRAJ10*01 TGTGCTGTGGGT T TCACGGGAGGAGGAAACAAACTC
ACCTTTT
unproductivea TRAV13-1*01 TRAJ29*01 TGTGCAGCAA TCC TCAGGAAACACACCTCTTGTCTTT
reT-3 mRNA productive TRAV8-3*01 TRAJ10*01 TGTGCTGTGGGT T TCACGGGAGGAGGAAACAAACTC
ACCTTTT
unproductivea TRAV13-1*01 TRAJ29*01 TGTGCAGCAA TCC TCAGGAAACACACCTCTTGTCTTT
Vb Db Jb 3’Vb N1-Db-N2 5’Jb
TCRB
H25-4 genome productive TRBV7-9*01 TRBD1*01 TRBJ2-5*01 TGTGCCAGCAGCTTA CGGGACAGGGTGCCG GAGACCCAGTACTTC
unproductive germline TRBD1*01 TRBJ2-7*01 TACAAAGCTGTAACATTGTG GGGACAACT CTACGAGCAGTACTTCGGGCCG
H254SeVT-3 genome productive TRBV7-9*01 TRBD1*01 TRBJ2-5*01 TGTGCCAGCAGCTTA CGGGACAGGGTGCCG GAGACCCAGTACTTC
unproductive germline TRBD1*01 TRBJ2-7*01 TACAAAGCTGTAACATTGTG GGGACAACT CTACGAGCAGTACTTCGGGCCG
reT-1 mRNA productive TRBV7-9*01 TRBD1*01 TRBJ2-5*01 TGTGCCAGCAGCTTA CGGGACAGGGTGCCG GAGACCCAGTACTTC
reT-2.1 mRNA productive TRBV7-9*01 TRBD1*01 TRBJ2-5*01 TGTGCCAGCAGCTTA CGGGACAGGGTGCCG GAGACCCAGTACTTC
reT-3 mRNA productive TRBV7-9*01 TRBD1*01 TRBJ2-5*01 TGTGCCAGCAGCTTA CGGGACAGGGTGCCG GAGACCCAGTACTTC
PCR-amplified samples (H25-4: not shown; H254SeVT-3: shown in Figures 1J and 1K; reT-1, reT-2.1, and reT-3: shown in Figure 3B) were sequenced, then V, D, and J segment usages and junc-
tional sequences in CDR3were identified. Following reprogramming and redifferentiation, there were no alterations in gene rearrangement in either allele at the TCRA and TCRB gene loci. See Table
S1 for additional data on another T-iPSC clone (TkT3V1-7).
aOut-of-frame junction (at CDR3).
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Figure 3. Characterizations of Redifferentiated T Cells as T Cells
(A) Recognition of A24/Nef-138-8(WT) tetramer at 50–60 days after starting redifferentiation, analyzed by flow cytometry (upper panel). Tetramer-positive
cells were sorted by FACS or magnetically selected, then cultured for an additional 14 days, after which the expanded T cells were reanalyzed for tetramer
(lower panel).
(B) TCR mRNAs were identified in a SMART-mediated cDNA library for reT-1, reT-2.1, and reT-3 cells. GAPDH is an internal control for PCRs.
(C–E) Quantitative PCR to compare the expression of major cell surface molecules (C), cell lytic molecules (D), and transcription factors and signal-transduction
molecules (E) among PB CD4+, PB CD8+, reT-2.1, and H25-#4 cells. Individual PCR reactions were normalized against 18S rRNA.
(F and G) Global gene expression was analyzed using a cDNA microarray. Heat maps show the correlation coefficients between samples (F) and differential
expression (>3-fold) of genes relative to NK cells (G). Red and green colorations indicate increased and decreased expression, respectively.
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Figure 4. Redifferentiated T Cells Show T
Cell Functionality and the Same Antigen
Specificity as the Original CTL Clone
(A) Expansion ratios for reT-1, reT-2.2, and reT-3
cells elicited by PHA, IL-7, and IL-15 stimulation for
2 weeks. H25-#4 is the original clone. S19-#7 and
T26-#26 were other Nef-138-8(WT)-specific CTL
clones derived from different patients.
(B) Relative telomere length determined using flow-
FISH. Data are presented as mean ± SEM.
(C) Intracellular production of granzyme B (left
panel) and CD107a mobilization (right panel)
induced by stimulation of reT-2.1 cells with a-CD3/
CD28 beads or Nef-138-8(WT). Shaded plot:
stimulated cells, isotype antibody; gray line: un-
stimulated cells, granzyme B or CD107a antibody;
black line: stimulated cells, granzyme B or CD107a
antibody.
(D) IFN-g production in the presence of Nef-138-
8(WT) measured using ELISPOT. Data are pre-
sented as mean ± SD. N.D., not determined.
(E) Standard 51Cr release assay performed using
the indicated concentrations of Nef-138-8(WT).
Effector:target = 5:1.
See Figure S6 for additional data.
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mous cell expansion nor aberrant cell survival without cytokines
as leukemia cells was observed (data not shown). Taken
together, these data indicate that by passing through the T-
iPSC state, cloned cytotoxic T cells can become ‘‘rejuvenated’’
to central memory-like T cells with excellent potential for prolifer-
ation and survival.
RedifferentiatedCD8+ TCells Exhibit Antigen-Specific T
Cell Functionality
To determine whether redifferentiated CD8+ T cells exerted
cytotoxic effects upon recognition of specific peptides in the
context of an MHC, we performed functional assays using
HLA-A24-positive B-LCL cells as antigen-presenting cells.
Gag-28-9(WT) (KYKLKHIVW) is an antigenic peptide (aa 28–36)
from the HIV-1 Gag protein (Altfeld et al., 2006), whereas Nef-
138-8(2F) (RFPLTFGW) is a Tyr-to-Phe-substituted single-122 Cell Stem Cell 12, 114–126, January 3, 2013 ª2013 Elsevier Inc.residue mutant form of Nef-138-8(WT).
Both peptides were presented on HLA-
A24 cells.
One of the major mechanisms by which
CTLs induce cytotoxity is the secretion
of cytolytic molecules triggered by TCR
signaling. Intracellular staining revealed
that the cytolytic molecule granzyme B
was produced and stored in the granules
of redifferentiated CD8+ T cells (Figure 4C,
left column). CD107a, also known as lyso-
somal-associated membrane protein 1
(LAMP1), is a granulocyte membrane pro-
tein that transiently appears at the cell
surface and is coupled to degranulation
(secretion of cytolytic molecules) of the
stimulated CTLs, after which CD107a re-turns to the cytoplasm (Rubio et al., 2003). CD107a molecules
on the cell surface were captured by a fluorochrome-conjugated
antibodywhen redifferentiated CD8+ T cells were stimulatedwith
a-CD3/28 beads or Nef-138-8(WT) peptide, but not in the
absence of the beads or Gag-28-9(WT) peptide (Figure 4C, right
column). In the second experiment, we used the enzyme-linked
immunosorbent spot (ELISPOT) assay to assess cytokine
productivity per cell and confirmed that redifferentiated CD8+
T cells produced significant levels of IFN-g in response to stim-
ulation by its specific antigen, Nef-138-8(WT) (Figure 4D). In
a separate experiment, we used a 51Cr release assay to investi-
gate cytolytic capacity and found that redifferentiated CD8+
T cells lysed 51Cr-incorporated B-LCLs only when Nef-138-
8(WT) was presented on B-LCLs (Figure 4E).
These results are highly indicative that redifferentiated CD8+
T cells can release cytotoxic molecules and kill antigen-express-
ing target cells in an antigen-specific manner. Moreover,
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should broaden the therapeutic window for antigen-specific
T cell therapy by avoiding the troublesome mispairing TCRs
that can occur with the commonly used exogenous TCR transfer
technique for inducing antigen-specific T cells from hematopoi-
etic stem cells or peripheral mature T cells (Bendle et al., 2010;
Brenner and Okur, 2009).
DISCUSSION
Using a HIV-1-epitope-specific CTL clone as a model, we
demonstrated here that the reprogramming into pluripotency of
a T cell clone and the subsequent redifferentiation to mature
functional CD8+ T cells are possible. These redifferentiated
CD8+ T cells are highly proliferative naive cells with elongated
telomeres, and they exert T cell functions in the same HIV-1-
epitope-specific manner, permitting the inference that this
process of reprogramming and redifferentiation can rejuvenate
mature antigen-specific T cells.
Generation of iPSCs from T cells was initially difficult. On the
basis of reports by Seki et al. (2010), we also found that SeV is
suitable for the reprogramming of aged and exhausted fibro-
blasts, as well as of T cells. We also found that coexpression
of SV40 large T antigen acted synergistically with the classic
Yamanaka factors in enhancing the reprogramming efficiency
of T cells. Therefore, SV40 large-T antigen introduction using
the SeV vector system was also included in the protocol. Worth
noting is that c-MYC is a known oncogene, and when it is
inserted into the genomic DNA by the retroviral vector, it may
become a risk for tumorigenesis in the generation of iPSCs.
The same concern does not apply to SeV vector systems, given
that the genomic RNA could be removed from the cytosol after
reprogramming. Therefore, the utilization of SeV vectors both
improved reprogramming efficiency and shielded redifferentiat-
ing cells from oncogene- or provirus-mediated tumorigenesis
(Kohn et al., 2003).
In the redifferentiation experiments, mimicking TCR signaling
led to CD8-linage specification without reassembly of TCRA
genes. Preassembled TCR genes are a distinctive feature of
T-iPSCs not found on other pluripotent stem cells. TCRab is
aberrantly expressed on redifferentiating CD4/CD8 DN cells,
and the TCR signaling evoked results in the cessation of RAG
expression. Serwold and colleagues reported that aberrantly
early expression of TCR from preassembled Tcra and Tcrb
following TCR signaling in murine thymocytes drives later
lymphomagenesis (Serwold et al., 2010). They cautioned that
T-iPSCs might confer risk for TCR-mediated lymphomagenesis.
Therefore, the redifferentiation method will need to be further
optimized and confirmed for clinical safety before application
in practical treatments. This may be achieved by the use of an
inducible suicide-gene system for eliminating unwanted tumors
after injections (Hara et al., 2008; Veldwijk et al., 2004).
Immunological assays found that the redifferentiated CD8+
T cells exerted T cell functions such as cytolytic activity, IFN-g
secretion, and degranulation in a normal manner when stimu-
lated with their specific antigens. The most striking difference
was in their proliferation capacity and elongated telomeres,
which correlates with the central-memory T cell phenotype.
Stem cell-like memory T cells (TSCM) were recently identified asCea subpopulation of T cells that has the capacity for self-renewal
and that is multipotent and able to generate central memory,
effector memory, and effector T cells (Gattinoni et al., 2011;
Turtle et al., 2009). In a humanized mouse model, TSCM cells re-
constituted the T cell population more efficiently than other
known memory subsets while mediating a superior antitumor
response. It was found that inhibition of GSK3b enhances the
generation of TSCM in culture. Combining T-iPSC-mediated
T cell rejuvenation with GSK3b inhibition may therefore enable
efficient generation of TSCM cells and permit highly effective
immunotherapy along with the reconstitution of a normal T cell
immune system.
Although these data suggest that rejuvenated T cells enjoy an
advantage over the original T cell clone, it remains unclear
whether these HIV-epitope-specific rejuvenated T cells are
effective in improving the overall status of HIV infection. This is
because the role of CD8+ T cells in HIV infection appears to
vary depending on the disease stage (Appay et al., 2000; Borrow
et al., 1994; Brodie et al., 1999; Day et al., 2006; Koup et al.,
1994). Evasion of the immune response through CTL escape is
another important factor in HIV pathogenesis, and the escaped
virus is a substantial hurdle for HIV therapies (Phillips et al.,
1991). Therefore, this system may work best instead against
tumors such as amelanoma, for which certain antigenic epitopes
are known, or against viral infections other than HIV, for which
the roles of CD8+ cytotoxic T cells are more established. None-
theless, the systemdescribed in our studywill make it possible to
preserve and to supply highly proliferative, functional CD8+
T cells specific to a variety of HIV epitopes without worrying
about exhaustion. It may also act as a valuable tool in better
understanding the role of adoptive immunity in HIV infection.
Here, we have presented a proof of concept of CD8+ T cell
rejuvenation. The concept is not limited only to CD8+ cytotoxic
T cells. It may also be applied to CD4+ helper or regulatory
T cells to control desired or undesired immune reactions in the
context of malignancies, chronic viral infections, autoimmune
diseases, or transplantation-related immune disorders, if optimi-
zation of redifferentiation conditions can be achieved. Biological
and technical challenges lie ahead, but the data presented in this
work open new avenues toward antigen-specific T cell therapies
that will supply unlimited numbers of rejuvenated T cells and will
regenerate patients’ immune systems.
EXPERIMENTAL PROCEDURES
Generation of Antigen-Specific CTL Clones
Nef138-8(WT)-specific CTL lines were induced from PBMCs of a patient
chronically infected with HIV-1 who is positive for HLA-A24, as described
(Kawana-Tachikawa et al., 2002). Each CTL line was expanded from
a single-cell sorted tetramer+ T cell, and the cells in every CTL line were
confirmed for expression of only one kind of TCRab. For more details of
CTL-clone establishment, see the Supplemental Experimental Procedures.
Generation of T-iPSCs
Human iPSCs were established from PB T cells or a CTL clone as described
(Takayama et al., 2010), slightly modifying the culture conditions. In brief,
T cells were stimulated by a-CD3/CD28 antibody-coated beads (Miltenyi Bio-
tec) or by 5 mg/ml PHA-L (Sigma-Aldrich). The activated cells were transduced
with reprogramming factors via retroviral or SeV vectors and were cultured in
RH10 medium (RPMI-1640 supplemented with 10% human AB Serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 ng/ml streptomycin), which wasll Stem Cell 12, 114–126, January 3, 2013 ª2013 Elsevier Inc. 123
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medium/F12 FAM supplemented with 20% knockout serum replacer, 2 mM
L-glutamine, 1% nonessential amino acids, 10 mM 2-mercaptoethanol, and
5 ng/ml basic fibroblast growth factor [bFGF]). The established iPSC clones
were transfected with small interfering RNA L527 (Nishimura et al., 2011) using
Lipofectamine RNAi Max (Invitrogen) for removal of SeV vectors from the
cytoplasm.
Analysis of TCR Gene Rearrangement in Genomic DNA
Genomic DNA was extracted from approximately 53 106 cells using QIAamp
DNA kits (QIAGEN) according to the manufacturer’s instructions. For TCRB
gene rearrangement analysis, PCR was performed according to BIOMED-2
protocols (van Dongen et al., 2003). For TCRA gene rearrangement analysis,
PCR was performed using the primers shown in Figure S2 and LA Taq HS
(TaKaRa). The PCR protocol entailed three amplification cycles (30 s at
95C, 45 s at 68C, and 6 min at 72C); 15 amplification cycles (30 s
at 95C, 45 s at 62C, and 6 min at 72C); and 12 amplification cycles (15 s
at 95C, 30 s at 62C, and 6 min at 72C). The dominant band within the ex-
pected size range was purified using a QIAquick gel-extraction kit (QIAGEN)
and was then sequenced. V, D, and J segment usages were identified by
comparison to the ImMunoGeneTics (IMGT) database (http://www.imgt.org/)
and by using an online tool (IMGT/V-QUEST) (Lefranc, 2003). Gene-segment
nomenclature follows IMGT usage.
Analysis of TCR Gene Rearrangement in mRNA
A method based on the ‘‘switch mechanism at the 50-end of the reverse
transcript (SMART)’’ (Du et al., 2006) was used to synthesize double-stranded
cDNAs (Super SMART cDNA synthesis kit; BD Clontech). Reverse tran-
scription was conducted with the 30 SMART CDS primer, SMART II A oligonu-
cleotides (Super SMART cDNA synthesis kit), and PrimeScript Reverse
Transcriptase (TaKaRa) for 90 min at 42C. Double-stranded cDNA was then
synthesized and was amplified with 50 PCR Primer II A (Super SMART cDNA
synthesis kit), and reagents were provided in an Advantage 2 PCR Kit (BD
Clontech). The PCR protocol entailed 20 cycles of 5 s at 95C, 5 s at 65C,
and 3 min at 68C. The amplified double-stranded cDNA was used as
templates in TCRA- or TCRB-specific amplification reactions. With forward
primer (2nd_50-SMART) and reverse primer (30-TRAC for TCRA or 30-TRBC
for TCRB), 25 cycles of amplification were performed (30 s at 94C, 30 s at
55C, and 1min at 72C). PCR products were cloned into pGEM-T Easy Vector
(Promega) and were sequenced.
T Cell Differentiation from T-iPSCs
To differentiate human iPSCs into hematopoietic cells, we slightly modified
a previously described protocol (Takayama et al., 2008). Small clumps of
iPSCs (<100 cells) were transferred onto irradiated C3H10T1/2 cells and co-
cultured in EB medium (Iscove’s modified Dulbecco’s medium supplemented
with 15% fetal bovine serum [FBS] and a cocktail of 10 mg/ml human insulin,
5.5 mg/ml human transferrin, 5 ng/ml sodium selenite, 2 mM L-glutamine,
0.45 mM a-monothioglycerol, and 50 mg/ml ascorbic acid) in the presence of
VEGF, SCF, and FLT-3L. Hematopoietic cells contained in iPSC sacs were
collected and were transferred onto irradiated OP9-DL1 cells (provided by
RIKEN BRC through the National BioResource Project of the Ministry of
Education, Culture, Sports, Science, and Technology [MEXT]) (Watarai et al.,
2010). The hematopoietic cells underwent T lineage differentiation on OP9-
DL1 cells during coculture in OP9 medium (aMEM supplemented with 15%
FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 ng/ml streptomycin) in
the presence of FLT-3L and IL-7. The T lineage cells were then harvested,
mixed with irradiated HLA-A24 PBMCs, and cocultured in RH10 medium in
the presence of IL-7 and IL-15.
Intracellular Staining
For intracellular staining of granzyme B, T cells were stimulated by a-CD3/28
beads or peptide-loaded HLA-A24+ B-LCLs. After 2 hr, brefeldin A (5 mg/ml;
Invitrogen) was added, with incubation for 4 hours more. Cells were then har-
vested and fixed in Fixation/Permeabilization solution (BD Biosciences). Intra-
cellular staining was performed as per the manufacturer’s protocol using
Perm/Wash buffer (BD Biosciences) and fluorescein isothiocyanate (FITC)-
conjugated granzyme B antibody (BD Biosciences). For capturing CD107a124 Cell Stem Cell 12, 114–126, January 3, 2013 ª2013 Elsevier Inc.transiently expressed on cell surfaces, T cells were incubated with a-CD3/28
beads or peptide-loaded HLA-A24+ B-LCLs and were cultured with FITC-
conjugated CD107a antibody (BioLegend) for 6 hr. Harvested cells were fixed
and stained as described above. Data were acquired on FACSAria II equip-
ment (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Measurement of Telomere Length by Flow-FISH
Telomere length was measured using a Telomere PNA Kit/FITC (DAKO) as
previously described (Neuber et al., 2003).
ELISPOT and 51Cr Release Assays
The antigen-specific responses of T cells were measured using an ELISPOT
assay for IFN-g and a standard 51Cr release assay as described (Kawana-
Tachikawa et al., 2002; Tsunetsugu-Yokota et al., 2003). HLA-A24+ B-LCLs
were used as antigen-presenting cells.
Statistics
All data are presented as mean ± SD. All statistics were performed using Excel
(Microsoft) and Prism (GraphPad software) programs, applying two-tailed
Student’s t test. Values of p < 0.05 were considered significant. For additional
details, see the Supplemental Experimental Procedures.
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